Mid
T
TGTXAI Stock Diagnostic Report
TG Therapeutics targets $890M-$905M 2026 U.S. BRIUMVI net revenue while anticipating subcutaneous Phase III results around year-end
TG Therapeutics has provided a positive outlook, setting a target for BRIUMVI's net sales in the U.S. for 2026 at $890 million to $950 million.
View Source Article ↗AI CATALYST SCORE85 / 100Score computed by Sentinel V12
REFERENCE PRICE$46.70000076293945Reference entry price at analysis time
01
FUNDAMENTALS
Financial & Fundamental Analysis
The 2026 U.S. BRIUMVI net sales target has been raised to $890M-$905M, demonstrating that the fundamental growth trend remains valid.
02
CATALYST & STRATEGY
Catalyst Analysis & Forward Strategy
TG Therapeutics is targeting U.S. BRIUMVI net sales of $890M-$905M for 2026 and is set to announce Phase III clinical results for the subcutaneous injection around the end of the year.